Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype
Kreps LM., Yakubovich E., Zhao H., Yimer S., Yang E., Cruz J.
Prospective Study, published in J Bone Oncol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Bone Oncol (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41777792
- PMCID
- PMC12950464
- DOI
- 10.1016/j.jbo.2026.100754
- Citations
- 1
Abstract (original English)
The bone marrow microenvironment is highly saturated with bone marrow adipocytes (BMA), which differentiate from their precursor, mesenchymal stem cells (MSC). Evidence from patient trials suggests that bone marrow adiposity is increased in patients following some forms of chemotherapy. Moreover, it has been suggested that BMA can confer chemotherapeutic resistance to tumour cells, thereby ascribing a tumour-supportive role to BMA. We investigated the effect of chemotherapy on adipogenesis of human MSC in vitro, as well as potential underlying mechanisms leading to altered adipogenesis, and the effects in turn on tumour cell proliferation. Doxorubicin or carboplatin treatment of adipogenic differentiating MSC led to an increased percentage of mature BMA confirmed by increased gene expression of the adipocyte marker, PPARG . RNA-seq analysis identified significant increases in fibroblast growth factor (FGF) pathway genes in doxorubicin treated adipogenic differentiated MSC, which were validated at the mRNA and protein level. Notably, endogenous and secreted FGF2 was significantly increased with doxorubicin treatment. Furthermore, siRNA-mediated targeting of FGF2 impeded the doxorubicin-enhanced formation of lipid-containing mature BMA returning it to levels similar to vehicle control treated BMA. As FGF2 is a secreted protein we tested and confirmed that transfer of conditioned
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.